Phase I study of BAY 94-9027, a PEGylated B-domain-deleted  recombinant factor VIII with an extended half-life, in subjects  with hemophilia A.

Coyle, T E; Reding, M T; Lin, J C; Michaels, L A; Shah, A; Powell, J

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A.

Coyle, T E; Reding, M T; Lin, J C; Michaels, L A; Shah, A; Powell, J.

J Thromb Haemost ; 12(4): 488-96, 2014 Apr.

Article in En | MEDLINE | ID: mdl-24843882

Subject(s)

Factor VIII/chemistry; Factor VIII/pharmacokinetics; Hemophilia A/drug therapy; Peptide Fragments/chemistry; Peptide Fragments/pharmacokinetics; Polyethylene Glycols/chemistry; Adult; Animals; Hemophilia A/blood; Humans; Male; Middle Aged; Polyethylene Glycols/pharmacokinetics; Prospective Studies; Recombinant Proteins/chemistry; Recombinant Proteins/pharmacokinetics; Treatment Outcome; Young Adult

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptide Fragments / Polyethylene Glycols / Factor VIII / Hemophilia A Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Adult / Animals / Humans / Male / Middle aged Language: En Journal: J Thromb Haemost Journal subject: HEMATOLOGIA Year: 2014 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google